Nexvax2 - Celiac Disease

Nexvax2 is being developed to protect celiac disease (CeD) patients who carry the HLA-DQ2.5 immune recognition genes, from inadvertent gluten exposure.

Patients with the HLA-DQ2.5 genes account for more than 90% of the CeD population.

A global Phase 2 study assessing Nexvax2 is currently recruiting patients.